NYSE MKT LLC · APUS

+2.40% · +$0.0300 · Vol 24.8K

Apimeds Pharmaceuticals US Inc

Biotechnology

$1.28

+ Add to watchlist

Veridion Score

Loading

Score loading…

Veridion Score History · 90D

Composite trend over time

LOADING HISTORY…

REFRESHES DAILY

AI Analysis

Sovereign

Why is APUS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

About Apimeds Pharmaceuticals US Inc

PHARMACEUTICAL PREPARATIONS

Founded

—

Listed

2025

Employees

7

HQ

US

Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.

Company website →

Key statistics

Real vendor fields plus Veridion-computed history. Missing fields stay blank.

Open

$1.55

Day high

$1.55

Day low

$1.21

Previous close

$1.25

52W high

$1.55

-17.42% from high

52W low

$1.21

21% of range

Market cap

$19.3M

P/E

—

EPS

—

Dividend yield

—

Beta

—

Shares out

15.1M

Float

—

Volume

24.8K

Avg volume

—

VWAP

$1.37

Next earnings

—

Price history computed in-house

1W

-0.78%

1M

-0.78%

3M

-0.78%

1Y

-0.78%

YTD

-0.78%

SMA 50 $1.27 · above

SMA 200 $1.27 · above

52W position 21%

Veridion warehouse edge

Warehouse intelligence for APUS.

0: 941: 442: 123: —4: —5: —

No recent disclosure on file.

Insider activity

See Form 4 panel below.

Capital Web snapshots checked.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.

Data ledger

Quote and day range

Refresh interval: 30 seconds

Source: Market data

Veridion Score

Coverage building

Source: Veridion methodology

Chart and risk context

Daily bars with no missing-bar fill

Source: Market data

News and filings

Refresh intervals shown inside each panel

Source: Market news and federal filings

Financials

Loading quarterly statements…

SEC Form 4 ledger

APUS insider activity

Apimeds Pharmaceuticals US Inc

Score

Coverage building

Pressure

Mixed

Filings

0

Buys / sells

0 / 0

Net value

$0

Insiders

0

Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: $0 across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for APUS.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Congress · 90D

Loading PTR filings…

Federal contracts

APUS contract awards, year to date.

Public federal awards linked to this ticker.

—

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for APUS in this window.

Lobbying spend

APUS lobbying filings, year to date.

Registered lobbying filings matched to Apimeds Pharmaceuticals US Inc.

—

Refresh interval: 12hSource: LDA disclosure filings

No lobbying filings on file for APUS in this window.

Latest news · APUS

Refresh interval: 5 minutes · Source: Market news insights

Loading articles…

Analyst ratings

Sovereign unlock shows live analyst consensus for APUS.

Options

Sovereign unlock shows live options positioning for APUS.

Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.